Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Esophageal Cancer

Aliases
Esophageal Carcinoma, Esophagus Cancer, gastroesophageal junction cancer, Gastroesophageal Junction Cancer (1 other aliases)

140 clinical trials

152 products

31 drugs

Product
AB308
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Zimberelimab
Clinical trial
A Phase III, Multicenter, Open-label Study to Evaluate the Esophageal Stenosis Inhibition Effects and Safety of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
Status: Terminated, Estimated PCD: 2023-12-20
Product
CLS2702C/CLS2702D
Product
ASKB589
Clinical trial
A Phase III Study Evaluating the Efficacy and Safety of ASKB589 Combined With CAPOX and PD-1 Inhibitor as First-Line Treatment in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2026-12-30
Product
Capecitabine
Product
Oxaliplatin
Product
Tislelizumab
Product
Placebo
Clinical trial
nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Product
Ramucirumab + Paclitaxel
Product
Pembrolizumab
Product
IMU-131
Clinical trial
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Atezolizumab
Clinical trial
A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) and Trastuzumab in Combination With Capecitabine and Oxaliplatin (Xelox) in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (GEJ)
Status: Active (not recruiting), Estimated PCD: 2023-05-08
Product
TORL-2-307-MAB
Clinical trial
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Claudin 18.2 CAR-T
Clinical trial
A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Tebotelimab
Product
margetuximab
Product
Retifanlimab
Product
TORL-2-307-ADC
Clinical trial
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer
Status: Recruiting, Estimated PCD: 2025-01-15
Product
CBX-12
Clinical trial
A Phase II Study of Perioperative Disitamab Vedotin Plus Toripalimab and XELOX Versus Disitamab Vedotin Plus Toripalimab Versus XELOX in Subjects With HER2-expressing Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Status: Recruiting, Estimated PCD: 2025-01-31
Product
oxaliplatin
Product
Disitamab Vedotin
Product
Toripalimab
Product
ONC-392
Clinical trial
An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Status: Recruiting, Estimated PCD: 2024-06-30
Product
CBP-1019
Product
ZW25
Clinical trial
Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-12-07
Product
Docetaxel
Clinical trial
A Randomized，Multicenter, Open-Label，Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on r First-line Therapy
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Paclitaxel
Product
Infigratinib
Product
Cadonilimab
Clinical trial
A Phase II, Multicenter, Open-Label, Single Arm Study of Oral Infigratinib Monotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Who Harboring FGFR2 Gene Amplification
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Claudin 18.2
Product
VLS-1488
Clinical trial
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
Status: Active (not recruiting), Estimated PCD: 2024-03-20
Clinical trial
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
Status: Recruiting, Estimated PCD: 2026-09-26
Product
Nivolumab
Product
5-FU
Product
Cisplatin
Product
S-1
Clinical trial
A Phase II, Single-Arm Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Status: Terminated, Estimated PCD: 2023-11-17
Product
Tiragolumab
Product
Bemarituzumab
Product
Chemotherapy
Clinical trial
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Status: Recruiting, Estimated PCD: 2024-04-15
Product
Trastuzumab deruxtecan
Product
Ramucirumab
Product
AZD0901
Product
5-Fluorouracil
Product
Leucovorin
Clinical trial
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.
Status: Recruiting, Estimated PCD: 2025-05-02
Product
Nanoliposomal Irinotecan
Product
Gemcitabine
Product
l-leucovorin
Product
Irinotecan
Product
AZD7789
Product
Ga-OncoFAP
Clinical trial
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-01
Product
SGN-CEACAM5C
Clinical trial
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.
Status: Recruiting, Estimated PCD: 2025-07-29
Clinical trial
An Open-label Phase 1 Study to Investigate SGN-CEACAM5C in Adults With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2029-03-31
Product
Ramucirumab plus Paclitaxel
Clinical trial
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients With Select Relapsed Advanced Malignancies (JIVAN)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
Status: Recruiting, Estimated PCD: 2025-08-18
Product
mFOLFOX6
Product
AUR106
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2023-10-16
Product
TRK-950
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-08-31
Product
CAPOX
Product
SOX
Clinical trial
A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).
Status: Recruiting, Estimated PCD: 2026-03-17
Product
PF-07265028
Product
Sasanlimab
Clinical trial
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2023-11-28
Clinical trial
A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
Cyclophosphamide
Product
Ladiratuzumab vedotin
Product
pembrolizumab
Product
AK104
Clinical trial
A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-08-18
Product
AB-201
Product
Fludarabine
Clinical trial
A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors.
Status: Recruiting, Estimated PCD: 2023-07-01
Product
T3011
Clinical trial
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
TPST-1495
Clinical trial
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Advanced Solid Tumors or AK104 in Combination With Oxaliplatin and Capecitabine As First-line Therapy in Subjects With Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Product
5-fluorouracil
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Product
Sigvotatug Vedotin
Clinical trial
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-30
Product
carboplatin
Product
cisplatin
Clinical trial
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors
Status: Recruiting, Estimated PCD: 2030-01-31
Product
Disitamab vedotin
Product
tucatinib
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Status: Active (not recruiting), Estimated PCD: 2025-05-31
Product
paclitaxel
Product
CMG901
Clinical trial
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Status: Recruiting, Estimated PCD: 2026-07-01
Product
Evorpacept
Product
VE800
Product
Vancomycin
Clinical trial
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial
Status: Completed, Estimated PCD: 2020-10-30
Clinical trial
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Status: Completed, Estimated PCD: 2021-08-26
Clinical trial
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine
Status: Terminated, Estimated PCD: 2021-06-29
Product
SHR-1210
Product
CEA-targeted CAR-T cells
Product
SKB264
Product
trastuzumab
Product
ramucirumab
Product
BBI608
Clinical trial
A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
Status: Completed, Estimated PCD: 2017-09-20
Clinical trial
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-24
Product
Nab-paclitaxel
Clinical trial
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer
Status: Terminated, Estimated PCD: 2022-12-02
Product
BO-112
Product
BNT141
Clinical trial
Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
APL-101
Product
Donafenib tosilate
Clinical trial
A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy
Status: Terminated, Estimated PCD: 2020-10-29
Product
QBS10072S
Clinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
Status: Completed, Estimated PCD: 2022-09-21
Clinical trial
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
CEA CAR-T cells
Clinical trial
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Status:
Product
cabozantinib
Product
atezolizumab
Product
SL-279252
Product
GEN-001
Product
Avelumab
Clinical trial
A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With CAPOX Chemotherapy Compared to Placebo in Combination With CAPOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma
Status: Completed, Estimated PCD: 2023-07-09
Product
CS1001
Clinical trial
A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy forCEA-positive Advanced/Metastatic Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Study to Evaluate the Safety and the Efficacy of GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2020-05-27
Product
Ipilimumab
Product
Fluorouracil
Clinical trial
Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP)
Status: Recruiting, Estimated PCD: 2024-12-01
Drug
Tiragolumab
Drug
FOLFOXIRI
Drug
fluorouracil
Clinical trial
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Status: Recruiting, Estimated PCD: 2027-10-31
Drug
Atezolizumab
Drug
Docetaxel
Drug
mFOLFOX6
Clinical trial
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)
Status: Not yet recruiting, Estimated PCD: 2029-03-30
Product
Extended Dosing Interval
Product
Standard of Care
Clinical trial
Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China
Status: Active (not recruiting), Estimated PCD: 2025-04-28
Clinical trial
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-01
Product
KK2269
Clinical trial
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Status: , Estimated PCD: 2026-01-31
Drug
AN0025
Clinical trial
Phase I-II Study Chemoradiation in Elderly Patients With Oesophagus Cancer
Status: Recruiting, Estimated PCD: 2028-11-16
Clinical trial
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia
Status: Completed, Estimated PCD: 2021-07-01
Product
Carboplatin
Clinical trial
Phase III Multicenter Randomized Controlled Trial of PD-1 Inhibitor Combined With Preoperative Concurrent Chemoradiotherapy and Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (NEOCRTEC2101)
Status: Recruiting, Estimated PCD: 2031-01-01
Product
Sintilimab
Drug
Cisplatin
Clinical trial
16-161/1240
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Durvalumab
Product
Tremelimumab
Clinical trial
A Phase II Trial of Neoadjuvant Pembrolizumab for Resectable Early Stage Gastroesophageal Adenocarcinoma
Status: Terminated, Estimated PCD: 2023-03-11
Clinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2027-08-01
Product
AgenT-797
Drug
Botensilimab
Product
Balstilimab
Clinical trial
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study
Status: Active (not recruiting), Estimated PCD: 2023-03-11
Clinical trial
A Clinical Study of the Efficacy and Safety of Sintilimab in Combination With Chemotherapy (S-1/Oxaliplatin, SOX) and Radiotherapy for the Neoadjuvant Treatment of Locally Advanced Esophagogastric Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-06-30
Product
PD-1inhibitor
Clinical trial
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Aldesleukin
Clinical trial
Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Status: Recruiting, Estimated PCD: 2026-09-30
Product
CA-4948
Drug
5-FU
Drug
Trastuzumab
Product
mFOLFOX7
Clinical trial
An Open-Label, Phase II Single-Arm, Window Trial of Tadalafil Effect + Chemotherapy in Patients With Resectable Gastric/GEJ Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Tadalafil
Clinical trial
A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NEOCRTEC308)
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
Vinorelbine
Clinical trial
Phase Ib/II Study of Induction Chemotherapy and Durvalumab (MEDI4736) and Tremelimumab With Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-11-01
Drug
durvalumab
Product
Carboplatin AUC 2/Paclitaxel
Clinical trial
NEoadjuvant Total rX for Borderline Unresectable Esophageal Squamous Cell Carcinoma: a Prospective Randomized, Three-Arm, Open-Label Phase II Trial (NEXUS-2)
Status: Recruiting, Estimated PCD: 2026-12-31
Drug
UTD1
Clinical trial
A Randomized Trial Comparing Early Local Chemoradiation Therapy +/- Surgery Versus Systemic Therapy for Patients With Esophageal or Gastric Cancer With Oligometastases
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect
Status: Completed, Estimated PCD: 2022-01-20
Clinical trial
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status: Terminated, Estimated PCD: 2015-12-23
Clinical trial
Cadonilimab Combined With Induction Chemotherapy and Definitive Radiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Single-arm Trial (EC-CRT-006)
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
Cadonilimab
Clinical trial
A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2022-01-19
Drug
TAS 102
Clinical trial
An Early Exploratory Clinical Trial of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma.
Status: Recruiting, Estimated PCD: 2025-11-16
Product
Claudin18.2-Targeted Chimeric Antigen Receptor T Cell
Product
Panitumumab
Clinical trial
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Completed, Estimated PCD: 2019-12-23
Clinical trial
A Phase 1b/2a Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Product
TEW-7197
Clinical trial
A Phase II, Single Arm, Single Center Study of Cadonilimab(AK104) in Combination With Ivonescimab(AK112) Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Cancer
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Drug
AK104
Drug
Ivonescimab
Drug
XELOX
Drug
SOX
Clinical trial
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
IPH5301
Clinical trial
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet Chemotherapy
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Trifluridine/Tipiracil
Product
FOLFOX
Drug
T-VEC
Clinical trial
A Phase Ib/II Study of Regorafenib and Nivolumab Plus Chemotherapy in Patients With Unresectable Advanced/Recurrent Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
Regorafenib
Product
CapeOX
Clinical trial
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Immunotherapy Refractory Esophagogastric Adenocarcinoma
Status: Recruiting, Estimated PCD: 2026-04-01
Product
OBP-301
Clinical trial
Porphyromonas Gingivalis Elimination From Oral Improves Esophageal Cancer Patients Survival After Radical Operation
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
Tinidazole
Clinical trial
Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies
Status: Completed, Estimated PCD: 2018-05-29
Product
Epacadostat
Clinical trial
Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)
Status: Recruiting, Estimated PCD: 2027-02-22
Product
Zongertinib
Clinical trial
A Pilot Study of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Status: Completed, Estimated PCD: 2023-01-27
Product
Trastuzumab emtansine
Clinical trial
A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia
Status: Active (not recruiting), Estimated PCD: 2022-03-18
Drug
oxaliplatin
Drug
carboplatin
Drug
paclitaxel
Clinical trial
A Cancer Research UK Phase I/IIa Clinical Trial of BT1718, (A Bicycle Drug Conjugate) Given Intravenously in Patients With Advanced Solid Tumours.
Status: Completed, Estimated PCD: 2023-11-20
Product
BT1718
Clinical trial
Predicting Esophageal Cancer Borders Using PET-Imaging PEGASUS
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Randomized, Open Labeled Phase II Pilot Study of Total Neoadjuvant Chemotherapy With FLOT ( FLOT-TNT) VS Standard Perioperative FLOT ( FLOTPOP) in Patients With Gastric or GEJ Cancer, and Assessment of CTDNA as Correlative Biological Response
Status: Recruiting, Estimated PCD: 2028-10-01
Product
GSCF
Clinical trial
The IIT Study of Evaluation of Platelet-coupled IL-2 Cell Injection (P-IL-2) Single Agent and With Anti-PD-1 Monoclonal Antibody on the Safety, Tolerance and Preliminary Effectiveness in Patients With Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-31
Product
P-IL-2
Product
P-IL-2 plus Anti-PD-1 Monoclonal Antibody
Clinical trial
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
olaparib
Clinical trial
A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status: Terminated, Estimated PCD: 2022-01-07
Product
Taladegib
Clinical trial
Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction: a Single-arm,Open-label，Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Serplulimab
Clinical trial
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2014-07-15
Product
Cixutumumab
Clinical trial
A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma
Status: , Estimated PCD: 2015-03-06
Product
AMG 337
Clinical trial
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase II Study of Irinotecan and Taxotere With Concurrent Radiotherapy as a Preoperative Treatment in Resectable Esophageal Cancer
Status: Completed
Product
Taxotere
Clinical trial
An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2023-06-30
Product
CT048
Clinical trial
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340) - The DANTE Trial
Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Status: Active (not recruiting), Estimated PCD: 2023-03-15
Product
Avelumab addition to perioperative chemotherapy
Clinical trial
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-05-31
Drug
PD-1 monoclonal antibody
Product
Albumin paclitaxel
Drug
Nedaplatin
Clinical trial
Safety and Efficacy of Pembrolizumab in Combination With FLOT as a First-line Treatment in Patients With Gastroesophageal Junction Cancer: a Prospective Multicenter Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Product
Pembrolizumab plus chemotherapy
Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Status: Recruiting, Estimated PCD: 2034-12-30
Product
Entinostat
Product
Montanide ISA-51 VG Adjuvant
Product
H1299 Cell Lysates
Clinical trial
A Prospective, Single-arm Multicenter Clinical Trial of Envafolimab Combined With Abraxane and Cisplatinas in Resectable Esophageal Squamous Cell Cancer
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Drug
Envafolimab
Drug
Abraxane
Clinical trial
HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HMBD-001
Clinical trial
PALEO: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer Complications
Status: Recruiting, Estimated PCD: 2027-07-31
Clinical trial
CALIBRATION: An Exploratory Study in Patients With Advanced Oesophageal Malignancies Receiving MEDI4736 (Durvalumab), Investigating Whether Early Changes in Circulating Tumour DNA Can Predict Tumour Response
Status: Active (not recruiting), Estimated PCD: 2021-11-11
Clinical trial
A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) : A Single-Arm Phase II Clinical Trial
Status: Completed, Estimated PCD: 2023-09-30
Drug
PD-1 antibody
Product
Paclitaxel-albumin
Clinical trial
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
Status: Active (not recruiting), Estimated PCD: 2022-10-19
Product
Rucaparib
Clinical trial
Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma
Status: Completed, Estimated PCD: 2019-12-01
Product
FOLFIRI
Clinical trial
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Status: Terminated, Estimated PCD: 2022-12-30
Clinical trial
A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.
Status: Completed, Estimated PCD: 2023-02-06
Product
Oxaliplatin+Capecitabine+Pembrolizumab
Clinical trial
Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Status: Completed, Estimated PCD: 2021-12-01
Drug
pembrolizumab
Clinical trial
Sintilimab Combined With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherapy for Conversion Therapy in Unresectable Stage IV Gastric Cancer: a National Multicenter Randomized Controlled Study
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel
Product
Sintilimab + S-1 + nab-paclitaxel
Clinical trial
Nordic Gastric and Esophageal Tumor Study
Status: Completed, Estimated PCD: 2022-12-28
Product
Proton pump inhibitor
Clinical trial
A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Product
SHR-A2102；Adebrelimab；Cisplatin